title: The effect of admission blood pressure on the prognosis of patients with intracerebral hemorrhage that occurred during treatment with aspirin, warfarin, or no drugs.
abstract: BACKGROUND
  Hypertension is the most important modifiable risk factor for intracerebral hemorrhage (ICH), but blood pressure (BP) management during the acute phase of ICH is still controversial. Approximately one-fourth of ICHs occur during treatment with warfarin or aspirin.
  
  
  OBJECTIVE
  This study was designed to determine the effect of admission BP on the early prognosis of ICH patients by dividing them into three groups (warfarin, aspirin, and no drugs).
  
  
  METHODS
  Three hundred and sixty-nine patients with supratentorial ICH were divided into three groups according to medication. Each group was evaluated in terms of prognosis and the risk for mortality based on the modified Rankin Scale (mRS) score at discharge (good prognosis: mRS ≤ 3; poor prognosis: mRS > 3). The effect of admission BP on prognosis was evaluated for each group.
  
  
  RESULTS
  The in-hospital mortality rate was 72% for ICH patients treated with warfarin, 41.6% for ICH patients treated with aspirin, and 35% for ICH patients treated with no drugs. Admission mean arterial blood pressure (MABP) values were higher in patients with poor prognosis compared with patients with good prognosis for the aspirin (P = .002) and no-drug (P = .001) groups, but not in the warfarin (P = .067) group.
  
  
  CONCLUSIONS
  A high MABP at admission was found to be an independent predictor of poor prognosis for ICH patients treated with aspirin or with no drugs, but not for ICH patients treated with warfarin.
authors.affiliation: Department of Neurology, School of Medicine, University of Ondokuz Mayis, Samsun, Turkey. kemalbalcidr@yahoo.com
authors.forename: Kemal
authors.initials: K
authors.lastname: Balci
authors.forename: Ufuk
authors.initials: U
authors.lastname: Utku
authors.forename: Talip
authors.initials: T
authors.lastname: Asil
authors.forename: Yahya
authors.initials: Y
authors.lastname: Celik
authors.forename: Ilkay
authors.initials: I
authors.lastname: Tekinaslan
authors.forename: Nasif
authors.initials: N
authors.lastname: Ir
authors.forename: Ercument
authors.initials: E
authors.lastname: Unlu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects*; D001794:Blood Pressure; D002543:Cerebral Hemorrhage / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D014859:Warfarin / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D000959:Antihypertensive Agents; D005343:Fibrinolytic Agents; D014859:Warfarin; D001241:Aspirin